Markers Useful in Monitoring Radiation-Induced Lung Injury in Lung Cancer Patients: A Review.

ABSTRACT: In 2018, lung cancer was the most common cancer and the most common cause of cancer death, accounting for a 1.76 million deaths. Radiotherapy (RT) is a widely used and effective non-surgical cancer treatment that induces remission in, and even cures, patients with lung cancer. However, RT faces some restrictions linked to the radioresistance and treatment toxicity, manifesting in radiation-induced lung injury (RILI). About 30-40% of lung cancer patients will develop RILI, which next to the local recurrence and distant metastasis is a substantial challenge to the successful management of lung cancer treatment. These data indicate an urgent need of looking for novel, precise biomarkers of individual response and risk of side effects in the course of RT. The aim of this review was to summarize both preclinical and clinical approaches in RILI monitoring that could be brought into clinical practice. Next to transforming growth factor-?1 (TGF?1) that was reported as one of the most important growth factors expressed in the tissues after ionizing radiation (IR), there is a group of novel, potential biomarkers-microRNAs-that may be used as predictive biomarkers in therapy response and disease prognosis.

SUBMITTER: Sliwinska-Mosson M 

PROVIDER: S-EPMC7565537 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature